Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Biotech
Exelixis’ Cabometyx successor misses primary endpoint in CRC trial
While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu
Jun 22, 2026 3:40pm
BridgeBio preps approval push for dwarfism drug after ph. 3 win
Feb 12, 2026 7:30am
Fierce Pharma
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
Dec 18, 2025 7:55am
ESMO: Exelixis' TKI reduces risk of death by 20%
Oct 20, 2025 2:30am
